

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX-0207

Inventors:

Macina et al.

Serial No.:

09/867,034

Filing Date:

May 29, 2001

Examiner:

Davis, Natalie, A.

Group Art Unit:

1642

Title:

Method of Diagnosing, Monitoring, Staging, Imaging and Treating Colon

Cancer

"Express Mail" Label No. EV 044354378 US Date of Deposit - February 22, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C_d 20231.

Typed Name: Kathleen A/Tyrrell

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Reply to Restriction Requirement

This is a reply to the Restriction Requirement dated

January 23, 2002 setting a one (1) month statutory period for

response. Please enter the following remarks into the record.

REMARKS

Claims 1 through 14 are pending in the instant application.

Claims 1 through 14 has been subjected to a Restriction

Requirement as follows:

RECEIVED

NAR O 6 2002

TECH CENTER 1800/2900

DEX-0207

Inventors:
Serial No.:

Macina et al. 09/867,034

Filing Date:

May 29, 2001

Page 2

Group I, claims 1(a) and (c) and 14, (as it reads on nucleic acids), drawn to a CSG polynucleotide and vaccine, classified in class 536, subclass 23.1;

Group II, claims 1(b) and 14 (as it reads on protein), drawn to a CSG protein and vaccine, classified in class 530, subclass 350;

Group III, claims 2-6, drawn to a method of diagnosing, staging and monitoring the presence and metastasis of colon cancer, classified in class 435, subclass 4;

Group IV, claim 7, drawn to a method of identifying potential therapeutic agents, classified in class 435, subclass 4;

Group V, claim 8, drawn to an antibody of claim 1, classified in class 530, subclass 387.9;

Group VI, claims 9-10, drawn to a method of imaging colon cancer, classified in class 424, subclass 1.49;

Group VII, claim 11, drawn to a method of treating colon cancer, classified in class 424, subclass 184.1; and

Group VIII, claims 12-13, drawn to a method of inducing an immune response, classified in class 514, subclass 2.

The Examiner suggests that these Groups are distinct inventions. Specifically, the Examiner suggests that the

DEX-0207

Inventors:
Serial No.:

Macina et al. 09/867,034

Filing Date:

May 29, 2001

Page 3

products of Groups I-II and V can be used with materially different processes than those of Groups III-IV and VI-VIII. In addition, with respect to Groups I, II and V, the Examiner suggests that the products are structurally and functionally different molecules with different immunological properties, modes of action, and half-life. With respect to Groups III-IV and VI-VIII, the Examiner suggests that they relate to methods with different steps, modes of operation, reagents needed and serve different endpoints and effects.

Applicants respectfully traverse this Restriction Requirement.

MPEP §803 provides two criteria which must be met for a restriction requirement to be proper. The first is that the inventions be independent or distinct. The second is that there would be a serious burden on the Examiner if the restriction is not required. A proper search of the prior art relating to the Group I, should also reveal art relating to the claims of Groups II though VIII. Thus, it does not appear that a serious burden would be placed upon the Examiner if restriction were not made.

Accordingly, since this Restriction Requirement does not meet both criteria as set forth in MPEP § 803 to be proper, it is respectfully requested that this Restriction Requirement be

DEX-0207

Inventors:
Serial No.:

Macina et al. 09/867,034

Filing Date:

May 29, 2001

Page 4

withdrawn.

However, in an earnest effort to be completely responsive, Applicants elect to prosecute Group I, claims 1(a) and (c) and 14, with traverse.

The Examiner has also suggested that a species election is required with respect to Groups I and II. Specifically, the Examiner suggests that applicant is required to elect a single species of CSG comprising either species A through V, drawn to SEQ ID NO: 1 through 22, respectively. The Examiner suggests that Species L-V are patentably distinct based on structural and functional differences.

Applicants respectfully disagree with this requirement.

In accordance with MPEP § 808.01, an election of species should be made when a generic claim recites such a multiplicity of species that an unduly extensive and burdensome search is required. In the instant case, however, the generic claim is not drawn to such a large multiplicity that search of all species would be unduly extensive or burdensome. Only 22 sequences have been set forth by the Examiner as different species.

Accordingly, reconsideration of this species election requirement is respectfully requested.

In an earnest effort to be completely responsive, however

DEX-0207

Inventors:

Macina et al. 09/867,034

Serial No.: Filing Date:

May 29, 2001

Page 5

Applicants elect Species E (SEQ ID NO:5), with traverse.

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record.

Respectfully submitted,

Kathleen A. Tyrrel

Reg. No. 38,350

Date: February 22, 2002

LICATA & TYRRELL P.C. 66 E. Main Street Marlton, New Jersey 08053

Maricon, New Jersey 08

(856) 810-1515

AMES DMENT TRANSMITTAL LETTER (Large Entity) Applicant(set Macina et al.						Docket No. DEX-0207	
Serial No. 09/867,034	1	Filing Date May 29, 2001		Examiner Natalie A. Davis		Group Art Unit 1642	
Invention: METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING COLON CANCER							
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below. CLAIMS AS AMENDED							
CLAIMS AS AMENDED							
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR		ER EXTRA S PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	14 -	20 =	=	0	x \$18	.00 \$0.00	
INDEP. CLAIMS	1 -	3 =	-	0	x \$84	-	
Multiple Depender	nt Claims (check if app	olicable)				\$0.00	
	-	TOTAL ADDITIO	NAL FEE FO	OR THIS AME	ENDMENT	- \$0.00	
Please chat A duplicate A check in Market Communic Communic A duplicate Market Any a	onal fee is required for large Deposit Account to copy of this sheet is in the amount of missioner is hereby aucation or credit any over the copy of this sheet is additional filing fees repatent application process.	No. enclosed. to cover the athorized to charge erpayment to Depotencies. equired under 37 C	e filing fee is a payment of sosit Account I	the following No. 50-1619		ciated with this	
Mathleen A. Tyrre	Signature ell, Registration No. 38	8, 350	Dated:	February 22,	2002		
Marlton, N.J. 08053 Tel: 856-810-1515					I certify that this document and fee is being deposited on with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.		

cc:

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence



CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EV 044354378 US Date of Deposit: February 22, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.A. 1.10 on the date indicated above and is addressed to the "BOX NON-FEE AMENDMENT", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Amendment Transmittal Letter (in duplicate);
- 2) Response to Restriction Requirement;
- 3) Return Postcard.

Mathleen A. Tyrkell

Kathleen A. Tyrkell

TECH CENTER 100 ROOM